Insider Purchases: Inside the Buy
Tag: GARP investing
🪶 Goosehead Insurance (GSHD): The C-Suite Double-Down on a Deeply Plucked Stock
Goosehead Insurance has been deeply plucked, but insiders are buying the dip while Q1 adjusted EBITDA surged 57%. With a tech-enabled, asset-light broker model, institutional ownership above the float, and short interest near 8%, GSHD offers a risky but fascinating GARP setup.
🖥️ CDW Corporation (CDW): The Tech Infrastructure Tollbooth Trading at an Uncharacteristic Discount
CDW Corporation may not build AI chips, but it helps organizations deploy the technology revolution. With insider buying, strong earnings, a growing buyback program, and a forward P/E of just 11.2x, this tech infrastructure giant could be trading at one of its most attractive valuations in years.
⚡ Celsius Holdings (CELH): Wall Street Panicked. Insiders Bought the Dip
Celsius Holdings (CELH) may no longer be just a trendy fitness energy drink brand. With explosive 138% revenue growth, synchronized insider buying, Alani Nu integration success, and PepsiCo’s distribution engine accelerating expansion, the stock increasingly looks like a high-growth GARP opportunity hiding beneath a brutal valuation reset.
🏗️ AECOM (ACM): The $26 Billion Backlog Infrastructure Giant Trading at 12x Earnings
AECOM (NYSE: ACM) may be one of the most misunderstood infrastructure stocks in the market. With a record $26.2 billion backlog, insider buying from top executives, and a surprisingly cheap valuation, this engineering and consulting powerhouse could be quietly laying the foundation for substantial long-term upside.
🎲 Flutter Entertainment (FLUT): Betting on the House at a 12x Discount
Flutter Entertainment (FLUT) has collapsed 69% from its highs, yet insiders are aggressively buying shares while FanDuel continues dominating U.S. sports betting. Is Wall Street underpricing one of the world’s most powerful gambling platforms?
🫀 Boston Scientific (BSX): A GARP Reset on a Medical Device Powerhouse
Boston Scientific stock has fallen nearly 48% from its highs, but the business engine remains strong. With double-digit revenue growth, major cardiovascular catalysts, director insider buying, low short interest, and a $2B buyback, BSX may be one of the cleaner large-cap healthcare GARP setups on the market.
🏗️ HubSpot (HUBS): From “Hubris” to “Hand-over-Fist”?
HubSpot (HUBS) just delivered strong Q1 2026 results, but the stock still plunged as investors questioned AI monetization, sales cycles, and valuation. With the CEO, founder-CTO, and director buying shares, institutions owning the float, revenue growing 23%, and valuation metrics finally looking reasonable, HUBS may be shifting from “growth at any price” to a serious GARP contender. 🏗️🤖📈
💼 Willis Towers Watson (WTW): The Quiet Compounder Smart Money Keeps Buying
WTW isn’t flashy—but when the CEO buys the dip and institutions own nearly everything, it’s worth a closer look. A quiet compounder trading at a rare discount.
🏟️ Sportradar (SRAD): The Picks & Shovels Powering the Global Betting Boom
Sportradar (SRAD) isn’t betting on games—it’s monetizing the entire betting ecosystem. With insiders loading up, free cash flow surging, and valuation resetting, this “picks & shovels” play may be one of the smartest ways to ride the global sports betting boom.